Influx HealthtechNSE:INFLUX +2.49%21 EBITDA Margin % is 20.53% as of Mar. 2026, which is 20% above its 10-year median of 17.11. GuruFocus rates NSE:INFLUX with a GF Score™ of 21/100. The stock has 4 warning signs investors should review. Among 954 Drug Manufacturers companies, Influx Healthtech ranks better than 70.65% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Influx Healthtech's EBITDA for the
six
months ended in Mar. 2026 was ₹164 Mil. Influx Healthtech's Revenue for the
six
months ended in Mar. 2026 was ₹801 Mil. Therefore, Influx Healthtech's EBITDA margin for the quarter that ended in Mar. 2026 was 20.53%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Influx Healthtech EBITDA Margin % Related Terms
Influx Healthtech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Influx Healthtech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:INFLUX vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Influx Healthtech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Influx Healthtech EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Influx Healthtech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Influx Healthtech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Influx Healthtech (NSE:INFLUX) has a EBITDA Margin % of 20.53% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Influx Healthtech and its competitors. This is 20% above median its historical median of 17.11. Over the past decade, Influx Healthtech's EBITDA Margin % has ranged from 10.41 to 21.24. According to the industry distribution chart, Influx Healthtech ranks #280 out of 954 companies in the Drug Manufacturers industry, placing it in the top 29.4%.
Is Influx Healthtech's EBITDA Margin % too high?
Influx Healthtech's current EBITDA Margin % of 20.53% is 20% above median its 10-year median of 17.11. Over the past 10 years, this metric has ranged from a low of 10.41 to a high of 21.24. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Influx Healthtech's value of 20.53% is 64% above this industry median. Based on the distribution chart, Influx Healthtech ranks #280 out of 954 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Influx Healthtech has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Influx Healthtech's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Influx Healthtech ranks #280 out of 954 companies for EBITDA Margin %. This puts Influx Healthtech in the upper half of its industry. The industry median EBITDA Margin % is 12.52. Influx Healthtech's value of 20.53% is 64% above this benchmark. Historically, Influx Healthtech's own EBITDA Margin % has ranged from 10.41 to 21.24 over the past decade. While the company's 10-year median is 17.11 vs. the industry median of 12.52, Influx Healthtech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Influx Healthtech's current EBITDA Margin % of 20.53% is 64% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Influx Healthtech and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Influx Healthtech's current EBITDA Margin % is 20.53%, which is 20% above median its own 10-year median of 17.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Influx Healthtech stock overvalued right now?
Influx Healthtech (NSE:INFLUX) has a current EBITDA Margin % of 20.53%. The current EBITDA Margin % is 20.53%, which is 20% above median its 10-year median of 17.11 and 64% above the Drug Manufacturers industry median of 12.52. Influx Healthtech's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Influx Healthtech (NSE:INFLUX), the current EBITDA Margin % is 20.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Influx Healthtech Ltd is a Mumbai-based, healthcare-focused company specialising in contract manufacturing. The company operates manufacturing facilities located in Thane. Its expertise spans the production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables. The company generates the majority of its revenue from sale of products.
21GF Score
Get the complete analysis for NSE:INFLUX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INFLUX has been successfully added to your 